Evaluation and Management of Drug-Drug Interactions in Patients Hospitalized in Nephrology and Post-Transplant Wards in a Teaching Hospital

  • Mojtaba Shafiekhani Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Sara Tarighati Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Ehsan Mirzaei Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Soha Namazi Mail Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Keywords:
Adverse Drug Events, Clinical Pharmacist, Drug Interaction, Immunosuppressive Agents, Kidney Transplantation

Abstract

Background: Kidney transplant patients usually take a combination of medications after transplantation; hence, medication safety becomes an important issue in order to maintain the new organ working properly. To evaluate the incidence and risk factors associated with potential drug-drug interactions (pDDIs) in hospitalized patients in Nephrology and Post-transplant wards to improve clinical management of pDDIs by a clinical pharmacist.
Methods: In this cross-sectional study, patients in Nephrology and Post-transplant wards were screened for pDDIs, using the interaction screening program Lexi-comp resource®. After evaluating the detected pDDIs for clinical relevance, the intervention was performed through physicians or nurses for type D and X drug interactions. Intervention feedback, implemented recommendations, and any probable adverse drug reactions were documented.
Results: During the study, 399 patients (239 in nephrology and 160 in post-transplant wards) plus 6105 drug orders were evaluated, and a total of 3263 DDIs were identified; of them, 827 (23.5%) were determined to be D and X classifications, and a total of 89.97% of all hospitalized cases had at least 1 pDDIs. Factors that had the greatest influence on pDDI incidence included the number of drugs and the admitted wards. Patients in the post-transplant ward experienced 2.3 times more DDIs than those in the nephrology ward. In total, 78% of class X and D DDIs required intervention, of which 75% were accepted and implemented by the physicians and nurses.
Conclusion: Clinically relevant pDDIs are common in patients in Nephrology and Post-transplant wards, and pharmacists play a critical role in detecting and managing this medical problem in hospitalized patients.

References

1. van den Bemt PM, Fijn R, van der Voort PH, Gossen AA, Egberts TC, Brouwers JR. Frequency and determinants of drug administration errors in the intensive care unit. Crit Care Med 2002;30(4):846-50.
2. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329(7456):15-9.
3. Wheeler AJ, Scahill S, Hopcroft D, Stapleton H. Reducing medication errors at transitions of care is everyone's business. Aust Prescr 2018;41(3):73-7.
4. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36(9):1331-6.
5. Espinosa-Bosch M, Santos-Ramos B, Gil-Navarro MV, Santos-Rubio MD, Marín-Gil R, Villacorta-Linaza P. Prevalence of drug interactions in hospital healthcare. Int J Clin Pharm 2012;34(6):807-17.
6. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009;65(8):757-73.
7. Wang HY, Chan AL, Chen M, Liao C, Tian Y. Effects of pharmaceutical care intervention by clinical pharmacists in renal transplant clinics. Transplant Proc 2008;40(7):2319-23.
8. Peter WLS. Improving medication safety in chronic kidney disease patients on dialysis through medication reconciliation. Adv Chronic Kidney Dis 2010;17(5):413-9.
9. Kaplan B, Mason NA, Shimp LA, Ascione FJ. Chronic hemodialysis patients. Part I: Characterization and drug-related problems. Ann Pharmacother 1994;28(3):316-9.
10. Mirkov S. Implementation of a pharmacist medication review clinic for haemodialysis patients. N Z Med J 2009;122(1297):25-37.
11. Mason NA, Bakus JL. Strategies for reducing polypharmacy and other medication‐related problems in chronic kidney disease. Semin Dial 2010;23(1);55-61.
12. Leendertse AJ, Egberts AC, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008;168(17):1890-6.
13. Ghods AJ. The history of organ donation and transplantation in Iran. Exp Clin Transplant 2014;12(suppl 1):38-41.
14. Saidi RF, Broumand B. Current challenges of kidney transplantation in Iran: Moving beyond the “Iranian Model”. Transplantation 2018;102(8):1195-7.
15. Manitpisitkul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens 2009;18(5):404-11.
16. Qiu C, Huang Y, Wang Q, et al. Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. Clin Infect Dis 2012;54(1):17-24.
17. Rama M, Viswanathan G, Acharya LD, Attur RP, Reddy PN, Raghavan SV. Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital. Indian J Pharm Sci 2012;74(1):63-8.
18. Fulton MM, Riley Allen E. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005;17(4):123-32.
19. MacKinnon NJ, Hepler CD. Preventable Drug-related Morbidity in Older Adults-1. Indicator Development. J Manag Care Pharm 2002;8(5):365-71.
20. Manley HJ, Cannella CA, Bailie GR, Peter WLS. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis 2005;46(4):669-80.
21. Joshua L, Devi PD, Guido S. Adverse drug reactions in nephrology ward inpatients of a tertiary care hospital. Indian J Med Sci 2007;61(10):562-9.
22. Pranabjyoti M, DM M. Profile of Adverse Drug Reaction in Patients with Renal Disorders. International Journal of Health Research and Medico Legal Practice 2017;3(1):51-4.
23. Dopour A, Hosseini F, Kanki K, Davoodpour S, Srinivas C, Shekar H. Prospective study on identification and assessment of potential drug-drug interactions in emergency medicine department at KIMS hospital and research centre. International Journal of Research in Pharmacy and Science 2016;6(1):36-39.
24. Reimche L, Forster AJ, van Walraven C. Incidence and contributors to potential drug‐drug interactions in hospitalized patients. J Clin Pharmacol 2011;51(7):1043-50.
25. Mannesse CK, Derkx F, De Ridder M, Man In't Veld A, Van Der Cammen T. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing 2000;29(1):35-9.
26. Namazi S, Pourhatami S, Borhani-Haghighi A, Roosta S. Incidence of potential drug-drug interaction and related factors in hospitalized neurological patients in two Iranian teaching hospitals. Iran J Med Sci 2014;39(6):515-21.
27. Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci 2009;12(3):266-72.
28. Shafiekhani M, Karimi S, Davarpanah Ma, Vazin A. Evaluating drug interactions, adverse drug reactions, and level of adherence to highly active antiretroviral therapy regimen amongst HIV-positive patients who referred to an AIDS healthcare center in Fars, southern Iran: the first multifaceted study from Iran. HIV &m AIDS Review. International Journal of HIV-Related Problems 2017;16(1):24-31.
29. Jankovic SM, Pejcic AV, Milosavljevic MN, et al. Risk factors for potential drug-drug interactions in intensive care unit patients. J Crit Care 2018;43:1-6.
30. Köhler G, Bode-Böger S, Busse R, Hoopmann M, Welte T, Böger R. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000;38(11):504-13.
31. Riechelmann RP, Moreira F, Smaletz Ò, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 2005;56(3):286-90.
32. Sharma S, Chhetri HP, Alam K. A study of potential drug-drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal. Indian J Pharmacol 2014;46(2):152-6.
33. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug–drug interactions at hospital entry and during hospital stay of patients in internal medicine. European Journal of Internal Medicine 2008;19(6):413-20.
Published
2020-03-24
How to Cite
1.
Shafiekhani M, Tarighati S, Mirzaei E, Namazi S. Evaluation and Management of Drug-Drug Interactions in Patients Hospitalized in Nephrology and Post-Transplant Wards in a Teaching Hospital. J Pharm Care. 8(1):16-22.
QRcode
Section
Original Article(s)